Objective: Atrial fibrillation is the most common arrhythmia after cardiac surgery. Amiodarone can effectively prevent and control postoperative atrial and ventricular fibrillation. Acute hepatic damage after intravenous amiodarone, which can be fatal, is not well recognized. We describe three cases of acute hepatocellular injury after intravenous amiodarone administration in critically ill patients. Another 25 published cases and six cases reported to the Swiss Pharmacovigilance Center (Swissmedic) are discussed.
A miodarone is a class III antiarrhythmic agent used to treat atrial and ventricular arrhythmias, including atrial flutter and fibrillation. As a result of its long and variable half-life of 20 to 100 days, oral or intravenous loading doses are administered following different schedules over several days (1, 2) .
Atrial fibrillation is the most common arrhythmia after cardiac surgery with a peak incidence on postoperative days 2 and 3 (3) . Hospital length of stay after coronary artery bypass graft surgery can be extended by 2 to 4 days in patients developing atrial fibrillation with additional costs of several thousand dollars per patient (4 -6) . In addition, atrial fibrillation after cardiac surgery increases the risk of stroke (6, 7) and mortality (7) .
Amiodarone can prevent and convert postoperative atrial fibrillation (8 -11) . Compared with two other widely used antiarrhythmic drugs, sotalol and propafenone, amiodarone has been shown to be more effective for the prevention of atrial fibrillation (12) . Although there are more data confirming the role of amiodarone in the prevention of recurrent atrial fibrillation, it is also becoming a drug of choice in the treatment of atrial fibrillation, particularly in the postsurgical setting. In a recent metaanalysis, it was demonstrated that amiodarone is effective and apparently safe for converting atrial fibrillation to sinus rhythm in a wide range of patients (13) .
Amiodarone is associated with many adverse effects involving different organs. Although they are generally mild, 10% to 15% of patients require withdrawal of the drug as a result of toxicity. The most prominent adverse effects during longterm therapy with amiodarone include thyroid dysfunction, corneal microdeposits, and hepatic and pulmonary toxicity (14, 15) . Typical adverse effects of intravenous amiodarone administration are phlebitis at the injection site (16, 17) , sweating, heat sensation, nausea (18) , sinus bradycardia (19) , decrease of arterial pressure, shock, and atrioventricular block (20) or severe hypotension (21) . Long-term administration of amiodarone is associated with two types of liver toxicity. Asymptomatic elevation of transaminases up to three times the upper limit of normal (ULN) is frequent with a reported incidence of approximately 24% to 26% (22, 23) , whereas symptomatic liver injury is rare but potentially fatal (22, 24) . Acute hepatotoxicity during intravenous loading with amiodarone, however, is less well known.
We describe three cases of acute hepatocellular injury with an elevation of transaminases up to 17,000 U/L within 24 hrs after starting intravenous amiodarone loading. At the critical care unit at our institution, intravenous loading of amiodarone is administered according to the following regimen (3): on day 1, 300 mg within 30 mins, 60 mg/hr for the next 6 hrs, and 30 mg/hr for the remaining 17.5 hrs. On days 2 to 7, infusion of amiodarone is continued at a rate of 30 mg/hr or 720 mg/day. In the case of recurrent arrhythmias, additional boluses of 150 mg can be administered, but a daily dose of 2000 mg should not be exceeded (25) .
We also review 25 case reports of acute hepatocellular injury after starting intravenous amiodarone published between 1986 and 2004 (26 -45) and six cases reported spontaneously to the Pharmacovigilance Center of the Swiss Agency for Therapeutic Products (Swissmedic) , with a fatal outcome in four patients. Fully anonymized case reports, which do not include a study intervention, are considered a description of clinical practice and do not require an approval of our local state ethical committee, and a written, informed consent of the patient is not needed.
CASE REPORTS

Case 1
In a 66-year-old woman with coronary heart disease and heart failure (New York Heart Association [NYHA] grade III-IV), without a history of alcohol abuse or chronic acetaminophen intake, the mitral valve was replaced as a result of mitral insufficiency. Her medication at hospital admission was hormone replacement therapy with 2 mg estradiol per day and 1 mg norethisterone acetate per day, 5 mg amiloride per day, and 50 mg hydrochlorothiazide per day, 20 mg pravastatin per day, 0.0625 mg digoxin per day, 10 mg furosemide per day, phenprocoumon as necessary, 12.5 mg metoprolol per day, and oral amiodarone (100 mg/day) for a history of ventricular fibrillation. Pravastatin treatment, phenprocoumon, and hormone replacement therapy were stopped 1 day before surgery. Liver function tests on the day before the operation had been within normal limits.
Preoperatively, her ejection fraction (EF) was 48%, with a left ventricular end diastolic pressure (LVEDP) of 10 mm Hg. Immediately postoperatively, the patient had to be resuscitated mechanically during approximately 5 mins as a result of bradycardia. Under cardiac massage, mean arterial pressure (MAP) was always Ն50 mm Hg. The first hemodynamic measurement after successful pacing (V00) showed a cardiac output (CO) of 2.8 L/min and a cardiac index (CI) of 2.1 L/min/m 2 . After that, the CO remained stable between 3 and 4 L/min (1 L/min above the preoperative value), and MAP was Ͼ60 mm Hg.
On the day of surgery, a bolus of 200 mg amiodarone was administered intravenously for heart rate control because the patient's heart rate increased above 140 beats/min. Postoperative drugs were 150 mg furosemide for 2 days, 1.5 mg midazolam, 28 IU insulin, 10,000 IU heparin, 2 ϫ 600 mg acetylcysteine intravenously on the day of surgery for unclear reasons (at that time point, however, no signs of elevated liver function tests were observed), sucralfate, 2.75 mio U aprotinin, 2 mg morphine, and acetaminophen. Propofol at a dosage of 50 mg was started on day 1 for sedation and was continued throughout the hospital stay until postoperative day 14. On day 7, a native computer tomography of the head had to be performed as a result of increasing levels of unconsciousness and a history of cerebral vascular insufficiency with hemiplegic events. On days 1 to 11, she received 2 to 4 g per day acetaminophen, or a total of 34 g (average 3 g per day). On the day after intravenous amiodarone (first postoperative day), liver function tests showed a marked increase of ASAT (106 ϫ ULN) and ALAT (66 ϫ ULN). Intravenous amiodarone was stopped and replaced with intravenous digoxin (0.5 mg/day followed by 0.25 mg/ day) for heart rate control in atrial fibrillation. The hepatotoxicity was classified as an acute hepatocellular injury (46) . After having stopped intravenous amiodarone, biochemical parameters (creatinine), including liver function tests, improved or normalized ( Table 1) .
Of her prehospital medication, most drugs bear a small risk for hepatotoxicity (sexual hormones, hydrochlorothiazide, furosemide); however, these drugs are associated rather with cholestatic hepatotoxicity with jaundice than with hepatocellular injury. For metoprolol, one case of hepatitis, and for pravastatin, asymptomatic elevation of transaminases Ͼ3 ULN (1.4%) has been reported, but with the same incidence as placebo. Because pravastatin and metoprolol were stopped before the increase in liver function tests, they were considered unlikely to be causative agents.
Case 2
A 73-year-old woman was hospitalized for aortic valve replacement. The patient had no history of alcohol abuse or chronic acetaminophen intake. Before hospitalization, she received 100 mg low-dose aspirin per day, 20 mg pravastatin per day, 10 mg amlodipine per day, 1.75 mg glyburide per day, 50 mg atenolol per day, and 100 mg allopurinol per day. Glyburide, amlodipine, and allopurinol were stopped at admission. Pravastatin was given until the second postoperative day. Liver function tests were normal before the operation and thereafter until the administration of amiodarone intravenously.
The surgical procedure was uneventful, especially no episodes of hypotension were observed; MAP was never Ͻ70 mm Hg during surgery. Postoperatively, transesophageal echocardiography showed normal motility of the left ventricular wall, and the EF was normal (Ͼ70%).
The patient was transferred to the operative critical care unit, where she developed generalized convulsions soon after. She was initially treated with propofol before phenytoin loading was started. Concomitant medication included 100 IU insulin per day, 25,000 IU heparin per day, 40 mg furosemide per day, acetaminophen (1 g, 4 g, 2 g, 3 g, or a total of 10 g over 4 days until the fourth postoperative day), 10 mg propranolol three times per day, and 6 mg phenprocoumon on postoperative day 2. Morphine and propofol were given intravenously in variable doses as needed for analgesia and sedation. On postoperative day 3, she developed tachycardic atrial fibrillation. Propranolol was stopped and intravenous loading with amiodarone initiated (day 0). ASAT and ALAT were normal the morning amiodarone was started, but increased dramatically until midnight. Acetaminophen and intravenous amiodarone were stopped immediately, and phenytoin was replaced with lorazepam. Peak values of ASAT (485 ϫ ULN) and ALAT (206 ϫ ULN) were reached 14 hrs after starting amiodarone and decreased steadily during the following days. The liver damage was classified as acute hepatocellular injury (46) . On day 5, transaminases had improved significantly and the patient was transferred to the surgical ward (Table 1) .
Although the patient's medication before hospital admission (pravastatin, allopurinol, amlodipine) is associated with impaired liver function, these drugs were considered to be an unlikely cause for postoperative liver injury in this patient. All of these drugs had been stopped before liver injury developed, and the patient had normal transaminases before amiodarone was started. Considering the concomitant medication after surgery, a case of hepatitis has been reported with propofol, and hepatocellular injury has been reported with phenytoin. However, liver injury associated with phenytoin usually occurs 1 to 8 weeks after introduction of the drug and is associated with symptoms of hypersensitivity such as fever, rash, and eosinophilia. Because phenytoin was given for only 3 days, and symptoms of hypersensitivity were lacking, an association with phenytoin was considered to be unlikely.
Case 3
A 57-year-old man with coronary and valvular heart disease and heart failure (NYHA grade II-III) without a history of alcohol abuse or chronic acetaminophen intake was hospitalized for coronary bypass surgery. During surgery, a paravalvular leak of the pre-viously replaced aortic valve was closed. Preoperatively, he had an EF of 30%, which was confirmed after surgery. During surgery, MAP was between 50 and 80 mm Hg. His first postoperative MAP was 60 mm Hg with a CI of 3 L/m 2 . After surgery, his MAP subsequently increased to 80 mm Hg and he never had episodes of hypotension.
His medication before hospitalization included 2.5 mg bisoprolol per day, 5 mg enalapril twice per day, 0.125 mg digoxin per day, 20 mg furosemide per day, 5 mg torsemide per day, 75 mg venlafaxine per day, and oral amiodarone (200 mg three times per week). Oral amiodarone had been given on the day before and the day after surgery. Acetaminophen was started after surgery (day 2) and continued without interruption over the next 5 days (2 g, 3 g, 1 g, 3 g, 1 g per day, respectively, in total 10 g).
On the second postoperative day, he developed tachycardic atrial fibrillation and was treated with intravenous amiodarone. Because the amiodarone dose was adjusted to the preexisting amiodarone therapy, intravenous amiodarone was started with a bolus of 150 mg within 30 mins followed by infusion of 60 mg/hr for 6 hrs and 30 mg/hr from then on. Concomitant medication at this time included acetaminophen, 3.125 mg captopril per day, 5000 IU low-molecularweight heparin per day, 100 mg acetylsalicylic acid per day, 10 mg torsemide per day, 7.5 mg intravenous metoprolol per day, and 30 -50 g/min intravenous nitroglycerin. Preoperatively, ASAT and ALAT showed mild ele- 100 mg orally  33  59  44  10  106  5.7  0  200 mg intravenously  2.9  1  2454  3822  47  26  224  3.0  2  -2732  3307  59  18  197  -3  -2149  1780  73  20 ALAT, alanine-aminotransferase; ASAT, aspartate-aminotransferase; AP, alkaline phosphatase; INR, international normalized ratio; day 0 ϭ start of intravenous amiodarone administration.
a The normal range of the laboratory values are given in parentheses.
vations between 1-2 ϫ ULN. Within 24 hrs after rapid intravenous amiodarone infusion, ASAT and ALAT increased to 44 ϫ ULN and 51 ϫ ULN, respectively. Intravenous amiodarone was stopped immediately, as well as acetaminophen. After peaking (ASAT 85 ϫ ULN and ALAT 100 ϫ ULN), transaminases decreased steadily during the following days. The hepatotoxicity was classified as an acute hepatocellular injury (46) . On postoperative day 3, 200 mg oral amiodarone per day was reintroduced for heart rate con-trol after several episodes of tachycardic atrial fibrillation and failed attempts of electroconversion with values of ASAT and ALAT further declining (Table 1) . Concomitant medication with a potential for hepatotoxicity, particularly acetaminophen and captopril, were not stopped while transaminases began to decline steadily.
DISCUSSION
Acute liver injury after intravenous amiodarone is rare. Besides the three cases described here, we identified 25 case reports of acute liver toxicity associated with intravenous amiodarone published between 1988 and 2004, which are summarized in Table 2 (26 -41) . Two thirds of the patients received amiodarone for atrial fibrillation and one third for ventricular arrhythmias, mainly ventricular tachycardia. In approximately 68% of the cases, liver test abnormalities occurred within 24 hrs after starting amiodarone administration, in 20% within 2 to 3 days, and in the remaining with a ALAT, alanine-aminotransferase; ASAT, aspartate-aminotransferase; PT, prothrombin time; AP, alkaline phosphatase; INR, international normalized ratio; GGT, ␥-glutamyltranspeptidase; MD, missing data. delay of Ͼ3 days. In the majority of published reports, the pattern of symptoms and laboratory result abnormalities were similar to those described here. An increase in ALAT and ASAT Ͼtenfold ULN (range, 1300 -20,000 U/L) was seen in 22 of the 25 cases, an increase in total bilirubin with or without jaundice was observed in 50%, whereas renal impairment (mild to severe) or coagulation disorders were observed less frequently. In contrast to the three cases described here, none of the 25 cases in the literature underwent surgery. In 22 cases, forward failure was regarded as unlikely from the (sometimes limited) published information. In three cases (31, 35, 45) , forward failure cannot be completely excluded. Interestingly, this possibility has not been addressed by the respective authors.
In addition to the three cases described here, six patients with acute liver injury after intravenous administration of amiodarone were reported to the Pharmacovigilance Center of the Swiss Agency for Therapeutic Products (Swissmedic) between 1991 and 2001 (47) . In these patients, the mean amiodarone dose was 900 mg/day, and the onset of hepatotoxic symptoms was within 24 hrs in four of the six cases. All six patients had hepatocellular injury with a marked elevation of transaminases (ASAT up to Ͼ84 ϫ ULN, ALAT up to Ͼ70 ULN). Hyperbilirubinemia and centrilobular necrosis (in one patient with liver biopsy) were other predominant findings, corresponding well with histologic results (26, 27, 43) , showing also centro-or paracinar hepatocyte necrosis as a predominant finding. The mean duration of intravenous amiodarone treatment before onset of laboratory liver abnormalities was 3 days. In three patients, hepatotoxicity was reversible after stopping intravenous amiodarone, and-similar to our observations-oral rechallenge in one of these patients was tolerated without signs of hepatotoxicity. In one case, hepatic injury was still ongoing at the time of reporting and two patients had a fatal outcome.
Different mechanisms of hepatotoxicity of intravenous amiodarone have been postulated, including immunomediated centrilobular necrosis (27, 35, 43) or increased hepatic susceptibility to the toxic effects of amiodarone resulting from impaired liver function in patients with heart failure (29, 35) . Rhodes et al. (31) were the first to accuse polysorbate 80 to cause hepatotoxicity in association with intravenous amiodarone. Polysorbate 80 is a cosolvent used at a concentration of 10% to solubilize the lipophilic amiodarone (48) . This hypothesis is supported by the observation that two of the patients described in the literature and case 3 described here showed no or only mild liver function test abnormalities with oral amiodarone preceding intravenous administration (34, 37) . Furthermore, six patients (including case 3 in our series) recovered after stopping intravenous amiodarone, despite immediately starting therapy with oral amiodarone (30, 31, 37, 44) . Another two patients were rechallenged later with oral amiodarone and none of them showed any hepatotoxic effects (33, 41) . In contrast, three patients developed a second episode of acute hepatocellular injury after reexposure to intravenous amiodarone (37, 41, 43) . Alternatively, it cannot be excluded that the hepatotoxic effects associated with intravenous loading with amiodarone are related to higher amiodarone plasma and possibly liver concentrations after intravenous compared with oral administration. The risk of hepatotoxicity may also be related to the ratio of the plasma and liver amiodarone:N-desethylamiodarone (DEA) concentrations, which may be increased during the first days of intravenous loading with amiodarone. Furthermore, intravenous amiodarone may increase the concentration of other potentially hepatotoxic drugs by inhibiting their hepatic metabolism. Amiodarone and/or DEA inhibit effectively cytochrome P-450 (CYP) isozymes 2D6, 3A4, 2C9, 2C8 and, to lesser extent, CYP1A2, 2C19, 2A6, 2B6 as well as P-glycoprotein (49, 50) . Because DEA inhibits slightly CYP1A2, which is responsible for a minor part of acetaminophen metabolism (49) , an effect on the toxicity of acetaminophen cannot be excluded. However, liver injury associated with acetaminophen appears typically with a latency of 48 to 72 hrs, whereas in all three patients described here, transaminases had increased within 24 hrs after the start of intravenous amiodarone. Furthermore, this would not explain why switching to oral amiodarone or oral rechallenge were well tolerated, because the same enzymes are inhibited by oral administration as well.
The polysorbate hypothesis is supported by the description of hepatic injury in preterm infants with E-Ferol syndrome (51) . This syndrome is postulated to be a polysorbate 80-mediated hepatotoxic reaction after intravenous adminis-tration of a vitamin E formulation containing polysorbate as an excipient. However, a small animal in vivo toxicity study comparing the toxicities of alphatocopherol and alpha-tocopherol acetate in polysorbate did not reveal conclusive evidence about the nature of the toxic compound (52) .
The concentration of polysorbate 80 in the intravenous amiodarone formulation is 10% w/v (or 100 mg polysorbate/mL of a 50-mg amiodarone/mL solution) (48), corresponding to 2 mg polysorbate 80 per 1 mg amiodarone. This corresponds to a polysorbate 80 dose of 0.4 g, 1.44 g, and 1.78 g, respectively, to patient nos. 1-3 described in our report.
Data on toxicity of polysorbate 80 are scarce. Although the cytotoxic effects of polysorbate are possibly lower than other commonly used surfactants (53) , it acts as an emulgator. Therefore, polysorbate has membrane-fluidization properties (54, 55) . This fluidization potential might be sufficient to impair cell integrity and increase permeability of hepatocytes. On the other hand, centroacinar damage found in the liver biopsy of one patient reported to the Swiss Agency of Therapeutic Products and one of the case reports (27) does not support this possibility, because membrane permeabilization should affect particularly the peripheral parts of the liver lobules. Ex vivo, polysorbate 80 caused hemolysis and cholestasis in the isolated perfused rat liver (56) , as well as reversible accumulation of fat in rat hepatocyte cell lines already within 3 hrs after exposure (57) . In addition to its hepatotoxic effects, mild to moderate depression of the central nervous system after intraperitoneal or oral administration to rats and mice (58) , and after intracerebroventricular injection in rats, convulsions were observed (59) .
The fate of polysorbate in the body is only partially known. Pharmacokinetic investigations have shown that polysorbate 80 has a relatively short plasma halflife (60) , and that up to 90% of its polyethylene moiety is excreted renally within the first 12 hrs (61). Interestingly, polysorbate 80 is an inhibitor of the drug transporter P-glycoprotein (62) by impairing its adenosine triphosphatase (ATP-ase) activity. In addition, polysorbate 80 inhibits CYP3A4 (63) and may therefore inhibit amiodarone metabolism. Inhibition of P-gp and CYP3A4 by polysorbate 80 may both lead to higher amiodarone concentrations in hepato-cytes and therefore possibly increased amiodarone hepatotoxicity.
A second possibility by which polysorbate could induce hepatocellular damage is by impairing hepatic perfusion as a result of its well-known hypotensive effects (64 -66) . Under intensive-care unit conditions, continuous amiodarone is given through an infusion pump, and bolus application is performed as a shortterm infusion; nevertheless, hepatic hypoperfusion cannot be excluded. The histologic picture from two of the cases described here, namely centroacinar damage, is compatible with both hypoperfusion of the liver or toxic damage affecting the centroacinar parts of the liver lobules.
The three patients described here, as well as the 25 cases published in the literature, received various concomitant medications. These medications were checked for potential pharmacokinetic drug-drug interactions that might lead to increased amiodarone plasma concentrations. No pharmacokinetic interactions leading to a significant increase of amiodarone plasma concentrations were revealed (67, 68) .
A miodarone is a highly effective antiarrhythmic agent for the treatment and prevention of atrial and ventricular arrhythmias.
